$1,060,000 Settlement at Trial on Behalf of Livingston, New Jersey, Resident Who Suffered a Stroke During Surgery.
Sep 30, 2013OUTCOME: Settlement at trial
On September 30, 2013, the remaining defendant, my client’s cardiologist, settled all claims asserted against him during trial before he was scheduled to testify in our case in chief. Earlier, my clien ... t’s primary care physician settled all claims asserted against her the week before the trial began. The plaintiff was a resident of Livingston, New Jersey who suffered a stroke during prostate cancer surgery on June 11, 2007. The theory of the case was that his primary care physician and his cardiologist should have bridged him on Lovenox because his medical history revealed that he was hypercoaguable. When patients have a propensity to develop blood clots, they are sometimes medicated with Coumadin, which thins their blood and decreases the chance that they will form blood clots. When these patients have to undergo surgery, however, the dangers posed by their clotting disorder competes against the danger that they will bleed excessively during an operation because their ability to clot has been diminished as a result of medication. Patients who take anticoagulants like Coumadin usually take that medication orally. When doctors bridge patients who are on Coumadin, instead of taking a patient off of Coumadin five days or a week before surgery, doctors will substitute Coumadin with Heparin or Low Molecular Heparin which is easier to control because it is shorter acting. When patients are bridged, they can be kept on anticoagulants for up to a few hours before surgery, and they can be restarted on anticoagulants right after surgery. This reduces the time that patients have to be off of anticoagulants and decreases the window in which a patient’s hypercoaguability can cause a complication. The plaintiff was placed on life-long Coumadin during a hospital admission in January 2006, after he developed a blood clot and a pulmonary embolism while on prophylactic anticoagulants following knee surgery. During that episode he also developed atrial fibrillation. He was seen as an inpatient by the defendant cardiologist. Unfortunately, the cardiologist’s partners rounded on the patient while he was in the hospital thereafter, and the cardiologist was not aware that the other physicians caring for the patient had determined that he was genetically hypercoaguable and that he needed to be on lifelong anticoagulants. A year and six months later, the plaintiff was sent to his cardiologist and his primary care physician for preoperative clearance because he was scheduled to undergo prostate cancer surgery. Neither the cardiologist or the plaintiff’s primary care physician recommended that the plaintiff undergo bridging therapy, and the plaintiff was taken off anticoagulants a week before the surgery. While off anti-coagulants, the plaintiff experienced heart palpitations, which he ascribed to nerves in anticipation of surgery. According to some of his treating physicians and some of the experts who testified in the case, those palpitations were caused by recurring atrial fibrillation. As a result of atrial fibrillation, the plaintiff formed an embolus in his heart, which eventually went on to cause his stroke in the perioperative period. The case was tried in Newark, New Jersey between September 23, 2012 and September 30, 2013. I was in the middle of our case in chief when the defendant cardiologist consented to settle and his carrier began to negotiate. We had already called the plaintiff, his wife and son as witnesses. One of our experts, an ophthalmologist had already testified. The plan was to put the defendant cardiologist on the stand and to call our remaining experts, a cardiologist and a hematologist, and then rest.
